GlassScriptPhysician profile
Andrea Shea Westerbeck
NPI 1225737422
$2,965.73
in general payments reported to CMS, 2019-2025
27 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $725 · 2024: $1,204 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $601.37 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $476.50 | 2023-2025 | Erleada |
| Pfizer INC. | $297.16 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $235.35 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $153.05 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Urogen Pharma, INC. | $139.97 | 2023-2024 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $135.53 | 2024-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $104.25 | 2023-2025 | Pylarify |
| Accord Healthcare, INC. | $102.94 | 2023-2025 | |
| Immunitybio, INC. | $79.58 | 2024-2025 | |
| Boston Scientific Corporation | $78.93 | 2023-2025 | Greenlight Xps, Watchman Access System, Spaceoar Vue System - 10ml |
| Novartis Pharmaceuticals Corporation | $76.69 | 2023-2025 | |
| Tolmar, INC. | $62.83 | 2023-2025 | Jatenzo, Eligard |
| Astellas Pharma US INC | $61.54 | 2024-2025 | Xtandi |
| Ferring Pharmaceuticals INC. | $52.01 | 2025 | Adstiladrin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $42.33 | 2023-2025 | Altaviva, Interstim |
| Lantheus Medical Imaging, INC. | $29.66 | 2024 | |
| Tempus Ai, INC | $28.82 | 2024 | |
| Daiichi Sankyo INC. | $28.57 | 2025 | Enhertu |
| Procept Biorobotics Corporation | $27.33 | 2024 | Aquabeam System |
| Sun Pharmaceutical Industries INC. | $26.75 | 2023 | Yonsa |
| Ambu INC. | $26.14 | 2024 | |
| Endo USA, INC. | $22.48 | 2025 | Xiaflex |
| Azurity Pharmaceuticals, INC. | $22.21 | 2025 | Azmiro |
| Bluewind Medical | $20.16 | 2024 | Revi |
| Alnylam Pharmaceuticals INC. | $17.84 | 2023 | Givlaari |
| Amgen INC. | $15.74 | 2023 | Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Westerbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.